Trial · NCT05756621
Dual Anti-glutamate Therapy in Super-refractory Status Epilepticus After Cardiac Arrest
NCT05756621, Completed, University of Milano Bicocca
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Dual Anti-glutamate Therapy in Super-refractory Status Epilepticus After Cardiac Arrest. Trials, record NCT05756621. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05756621
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Dual Anti-glutamate Therapy in Super-refractory Status Epilepticus After Cardiac Arrest
- NCT number
- NCT05756621
- Status
- Completed
- Enrollment
- 84 participants, actual
- Lead sponsor
- University of Milano Bicocca
- Conditions
- Status Epilepticus, Cardiac Arrest
- Interventions
- Ketamine, Any anti-epileptic and anesthetic therapy, excluding Ketamine and Perampanel
- First posted
- 2023-03-06
- Last updated
- 2026-07-14
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of patients with resolution of status epilepticus | Over the entire period of stay in the Intensive Care Unit (up to 30 days) | Number of patients with resolution of status epilepticus, not followed by relapse and without the use of additional antiepileptic drugs, evaluated over the entire period of stay in the Intensive Care Unit, in the two groups DUAL versus OTHERS |
| Secondary | Number of patients with with time-locked resolution of status epilepticus | first 5 days after start of therapy | Number of patients with with resolution of status epilepticus 5 days after the start of therapy, not followed by relapse and without the use of additional antiepileptic drugs (only in the DUAL group) |
| Secondary | Number of patients with early favorable neurological outcome | Over the entire period of stay in the Intensive Care Unit (up to 30 days) | Number of patients with early favorable neurological outcome, defined as the patient's awakening (up to "command execution") during the stay in the Intensive Care Unit |
| Secondary | Number of patients with favorable long-term neurological outcome | 6 months after cardiac arrest | Number of patients with favorable long-term neurological outcome, defined by a modified Rankin scale score ≤ 2 at 6 months (minimum score 0, maximum score 6; lower scores indicate better outcomes) |
| Secondary | mortality in intensive care | Over the entire period of stay in the Intensive Care Unit (up to 30 days) | mortality in intensive care |
| Secondary | mortality at 6 months | 6 months after cardiac arrest | mortality at 6 months |
| Secondary | cumulative probability of resolution of status epilepticus | Over the entire period of stay in the Intensive Care Unit (up to 30 days) | incidence of the occurrence of resolution of status epilepticus, taking into account death as competing risk (cumulative incidence function) |
| Secondary | Number of patients with abnormal cholestasis indices | Over the entire period of stay in the Intensive Care Unit (up to 30 days) | Number of patients with abnormal cholestasis indices (GT-gamma \> 3 times the upper limit of normal) |
| Secondary | Number of patients with third degree atrioventricular block or cardiac arrest recurrence | Over the entire period of stay in the Intensive Care Unit (up to 30 days) | Number of patients with third degree atrioventricular block or cardiac arrest recurrence |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers11
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05756621
GET https://conductscience.org/api/trials/v1/NCT05756621/registered